These range from FDA approval to patent law, insurers, and the preferences of physicians and patients. Changes in any of these, some … Fortunately for biosimilars, the Affordable Care Act of 2010 outlined for the first time a fast-tracked approval process for biosimilars. Unfortunately, that process is still …
